By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

Halozyme Therapeutics, Inc. 

11388 Sorrento Valley Road

San Diego  California  92121  U.S.A.
Phone: 858-794-8889 Fax: 858-259-2539


SEARCH JOBS
Halozyme Therapeutics is a biopharmaceutical company dedicated to developing and commercializing innovative products that advance patient care. With a diversified portfolio of enzymes that target the extracellular matrix, the Company's research focuses primarily on a family of human enzymes, known as hyaluronidases, which increase the dispersion and absorption of biologics, drugs and fluids. Halozyme's pipeline addresses therapeutic areas, including diabetes, oncology and dermatology that have significant unmet medical need. The Company markets Hylenex® recombinant (hyaluronidase human injection) and has partnerships with Roche, Pfizer, Baxter, and Intrexon. Halozyme is headquartered in San Diego, CA. For more information on how we are innovating, please visit our corporate website at www.halozyme.com.

Key Statistics


Email: hr@halozyme.com
Ownership: Public

Web Site: Halozyme
Employees: 152
Symbol: HALO
 









Company News
Halozyme (HALO) Resumes Patient Enrollment And Dosing In PEGPH20 Clinical Trial With KEYTRUDA 7/25/2016 7:15:02 AM
Halozyme (HALO) To Host Second Quarter 2016 Financial Results Conference Call 7/12/2016 7:50:55 AM
Halozyme (HALO) Announces Agreement To Refinance Debt, Increases 2016 Guidance For Year-End Cash Balance 6/8/2016 8:09:23 AM
Halozyme (HALO) Presents Stage One Efficacy And Safety Analysis Of Phase 2 Clinical Study In Metastatic Pancreatic Cancer Patients Treated With PEGPH20 6/6/2016 9:45:13 AM
Halozyme (HALO) To Present At The UBS 2016 Global Health Care Conference 5/18/2016 7:41:57 AM
Halozyme (HALO) Reports First Quarter 2016 Financial Results 5/10/2016 7:58:49 AM
Halozyme (HALO) To Host First Quarter 2016 Financial Results Conference Call 4/21/2016 6:36:18 AM
Halozyme (HALO) Expands Oncology Pipeline With Two Compounds Designed For Activity In The Tumor Microenvironment 4/19/2016 6:34:01 AM
Halozyme (HALO) To Present Data From Five Preclinical Studies At AACR Annual Conference 3/17/2016 9:08:50 AM
Halozyme (HALO) Doses First Patient In Phase 3 Clinical Trial Of PEGPH20 In Combination With ABRAXANE And Gemcitabine 3/16/2016 6:47:42 AM
12345678910...
//-->